MindWalk Deploys OpenFold3 on AMD GPUs in Vultr Cloud for Drug Discovery
AMD's MI325X GPUs land a real production deployment for structure prediction — not a benchmark, actual drug-discovery workloads.
Why it matters
AMD is proving its inference capabilities against Nvidia in a high-value compute domain (biotech ML). This is a concrete data point in the GPU market competition, showing AMD gaining traction in specialized AI workloads beyond raw LLM inference.
The key facts
11 to knowOpenFold3 deployed on AMD Instinct MI325X GPUs
Production deployment (not pilot or announcement-only)
Vultr Kubernetes Engine + Vultr Cloud GPU infrastructure
AMD Inference Microservices (AIM) stack used
Drug discovery / structure prediction use case
September 2026 deployment date
OpenFold3 (open-source protein structure prediction) deployed in production
AMD Instinct MI325X GPUs used for inference
Deployment on Vultr Kubernetes Engine (cloud infrastructure)
Drug discovery / biotech use case
Date: September 21, 2026
Go to the source
EnterpriseAIhpcwire.com
Publisher excerpt: AUSTIN, Texas, Sept. 21, 2026 — MindWalk Holdings Corp., a Bio-Native AI company, today announced results from a production deployment of the open-source OpenFold3 structure prediction model, run with engineering partners AMD and Vultr on Vultr Kubernetes Engine and Vultr Cloud GPU powered by AMD…